<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787876</url>
  </required_header>
  <id_info>
    <org_study_id>2015-12-121</org_study_id>
    <nct_id>NCT02787876</nct_id>
  </id_info>
  <brief_title>Pegteograstim in Children With Solid Tumors</brief_title>
  <official_title>Efficacy and Safety of Pegteograstim on Chemotherapy-induced Neutropenia in Children With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in
      children with solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with solid tumor experience neutropenia after cytotoxic chemotherapy, and they
      usually receive granulocyte colony-stimulating factor (G-CSF) to stimulate neutrophil
      recovery. However it needs daily injection of G-CSF. Pegteograstim is a new formulation of
      PEGylated recombinant human G-CSF analogue pegfilgrastim. In this study, investigators aimed
      to evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in
      children with solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>Up to 3 weeks after the injection of pegteograsim</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of neutropenia (absolute neutrophil count (ANC) &lt; 500/uL)</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia (ANC &lt; 100/uL)</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest value of ANC</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with neutropenic fever</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chemotherapy Induced Neutropenia</condition>
  <condition>Pediatric Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Chemotherapy induced neutropenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegteograstim</intervention_name>
    <arm_group_label>Chemotherapy induced neutropenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with solid tumor who undergo chemotherapy with carboplatin, etoposide,
             doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE)
             regimen

        Exclusion Criteria:

          -  Patients with organ dysfunction (creatinine &gt; 2mg/dL, ejection fraction &lt;40% or severe
             arrhythmia/conduction disorder, other severe organ dysfunction)

          -  Hypersensitivity to pegteograstim, protein originated from E-coli, pegfilgrastim,
             filgrastim or latex.

          -  Patients with bleeding tendency to whom subcutaneous injection should be avoided.

          -  Active infection or infectious fever during the screening period.

          -  Genetic problem to fructose tolerance.

          -  Patients who participated in other clinical trial within 4 weeks before enrollment.

          -  Pregnant and nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ki Woong Sung, MD, PhD</last_name>
    <phone>82-2-3410-3529</phone>
    <email>kiwoong.sung@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Woong Sung</last_name>
      <phone>82-2-3410-3529</phone>
      <email>kwsped@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Ki Woong Sung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

